The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Paul Rutherford Carter net worth and biography

Paul Carter Biography and Net Worth

EVP of Gilead Sciences

Paul Carter’s background includes 10 years of experience at Gilead Sciences, Inc., in their Foster City, CA and London, UK offices, where he was employed as Executive Vice President, Commercial Operations from 2014 to 2016 and Senior Vice President and Head, International Commercial Operations from 2006-2014. Prior to that role, Mr. Carter spent 10 years at GlaxoSmithKline plc, where he served as Regional Vice President, China & Hong Kong from 2002 to 2005, Vice President and General Manager, Pharmaceutical & Consumer Health, Hong Kong & South China from 1999-2002, and General Manager, SmithKline Beecham Consumer Health, Russia & CIS from 1995 to 1999. Mr. Carter currently serves on the board of Hutchison China MediTech Ltd. (NASDAQ: HCM), a role he has held since 2017, where he is the Chairman of the Remuneration Committee and member of the Audit Committee, Nomination Committee and Technical Committee. Mr. Carter has also served as a board member of Mallinckrodt PLC (NYSE: MNK) since 2018, where he serves as a member of the Audit Committee. Mr. Carter is also the Chairman of Evox Therapeutics Ltd, a private biotechnology company based in Oxford, UK. Mr. Carter is also a board observer of Echosens SA, a private medical technology company. From 2015-2019, Mr. Carter was a board member, member of the Remuneration Committee, and Chair of the Audit Committee of Alder BioPharmaceuticals, Inc. In addition to his board memberships, Mr. Carter also serves as a healthcare advisor to numerous entities, including Astorg Partners SAS (2017 to present), ZambonGroup (2017 to present), Indegene Inc. (2017 to present) and GLG Institute (2017 to present). Mr. Carter holds a Bachelor’s degree in business studies from the University of West London.

What is Paul Rutherford Carter's net worth?: The estimated net worth of Paul Rutherford Carter is at least $5.78 million as of August 1st, 2016. Mr. Carter owns 64,122 shares of Gilead Sciences stock worth more than $5,783,163 as of November 23rd. This net worth estimate does not reflect any other investments that Mr. Carter may own. Learn More about Paul Rutherford Carter's net worth.
How do I contact Paul Rutherford Carter?: The corporate mailing address for Mr. Carter and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Paul Rutherford Carter's contact information.
Has Paul Rutherford Carter been buying or selling shares of Gilead Sciences?: Paul Rutherford Carter has not been actively trading shares of Gilead Sciences in the last ninety days. Most recently, Paul Rutherford Carter sold 2,000 shares of the business's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $79.81, for a transaction totalling $159,620.00. Following the completion of the sale, the executive vice president now directly owns 64,122 shares of the company's stock, valued at $5,117,576.82. Learn More on Paul Rutherford Carter's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 81,679 shares worth more than $6,935,730.32. The most recent insider tranaction occured on November, 6th when insider Merdad Parsey sold 25,590 shares worth more than $2,341,485.00. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 11/6/2024.

Paul Rutherford Carter Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/1/2016	Sell	2,000	$79.81	$159,620.00	64,122
7/1/2016	Sell	2,000	$83.12	$166,240.00	63,122
6/1/2016	Sell	2,000	$87.02	$174,040.00	63,122
5/2/2016	Sell	2,000	$88.72	$177,440.00	62,939
4/1/2016	Sell	2,000	$91.34	$182,680.00	63,122
2/1/2016	Sell	2,000	$82.32	$164,640.00	48,783
1/4/2016	Sell	2,000	$99.20	$198,400.00	48,783
10/1/2015	Sell	2,000	$98.59	$197,180.00	48,783
6/18/2015	Sell	10,000	$120.00	$1,200,000.00
4/8/2015	Sell	1,000	$100.00	$100,000.00
3/2/2015	Sell	2,000	$104.18	$208,360.00
12/1/2014	Sell	2,000	$100.02	$200,040.00
10/24/2014	Sell	2,000	$110.00	$220,000.00
10/1/2014	Sell	2,000	$106.39	$212,780.00
9/26/2014	Sell	2,000	$107.47	$214,940.00
8/26/2014	Sell	10,000	$106.16	$1,061,600.00
7/8/2014	Sell	16,728	$86.45	$1,446,135.60
6/9/2014	Sell	16,728	$79.43	$1,328,705.04
4/8/2014	Sell	16,728	$70.53	$1,179,825.84	28,562
3/10/2014	Sell	16,728	$79.32	$1,326,864.96	28,562

Paul Rutherford Carter Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $90.19

$89.27

$90.49

50 Day Range

MA: $87.43

$82.21

$97.90

2 Week Range

Now: $90.19

$62.07

$98.90

Volume

4,545,876 shs

Average Volume

7,529,191 shs

Market Capitalization

$112.40 billion

P/E Ratio

1,002.11

Dividend Yield

3.43%

Beta

0.17

Financial Prophecy

From Porter & Company | Ad